Ranbaxy Can't Split Antitrust Claims From Provigil Trial
By Kat Greene ( January 15, 2016, 8:23 PM EST) -- Ranbaxy Laboratories Inc. lost a bid to split certain claims from an upcoming trial in pay-for-delay litigation over sleep-disorder medicine Provigil when a Pennsylvania federal judge found Friday that the claims involve overlapping issues and can be heard together....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.